Smithers and CannaMetrix, LLC enter into an agreement to exclusively offer Biological Potency Testing

CannaMetrix’s EC50 cell-based assays are designed to measure receptor-level activity within the human endocannabinoid system, providing an additional data layer that can support product development, batch consistency studies, and scientific substantiation efforts. “Partnering allows Smithers to offer biological potency data alongside analytical testing, giving clients a more complete understanding of product performance. This analysis allows the industry to measure the entourage effect of minor cannabinoids and terpenes, and how complex formulations behave in biological systems,” said AJ McCardell, President, Smithers Cannabis Testing Services. CannaMetrix’s technology is protected by issued and pending U.S. patents and applies established pharmacological principles commonly used in other industries,  including EC50 dose-response modeling. The assays are compatible with a wide range of cannabis and hemp-derived products, including extracts, vapes, edibles,  beverages, tinctures, and pre-roll formulations. “With Smithers as our exclusive testing partner, this technology can be delivered with the quality systems, scientific rigor, and operational scale required for broader industry adoption,” said Harold Smith, CEO and Founder, CannaMetrix, LLC. “Our assays are designed to measure biological activity directly, rather than inferring potency from chemistry alone. By enabling a direct pairing of biopotency with the  chemical composition of products, producers will have additional scientific  rationale for formulating products, and customers will be able to make informed  choices.” The initial scope of the partnership will focus on biological potency testing services  supporting:

• Product development and formulation comparisons
• Batch-to-batch and process consistency assessments
• Stability and shelf-life evaluations

For more information about Smithers, please visit www.smithers.com/cannabis